About: MetaVia Inc., a clinical-stage biotechnology company, focuses on developing novel pharmaceuticals to treat cardiometabolic diseases. The company develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, as well as completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in Phase 1 trial for the treatment of obesity. Its therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. The company has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and Dong-A ST, a sole manufacturer for the production of DA-1241 and DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.39 (+3.73%)
MTVA NASDAQ MetaVia Inc.
MetaVia Inc. share price
MTVA price activity
Last Price
$1.390
Change (24hr)
0.05 USD (3.73%)
Volume
30.13K
Volume (4w avg)
-
Open
$1.35
Day Range
$1.35 - $1.39
Previous Close
$1.34
Last Trade
22 Oct, 8:00 pm GMT+0
Delayed
22 Oct, 8:00 pm GMT+0
MTVA price performance
Delayed
22 Oct, 8:00 pm GMT+0
MTVA Market Signals